Biodegradable polymeric nanoparticles as drug delivery devices

Kreuter, 1994, Nanoparticles, 219 1981 Langer, 2000, Biomaterials in drug delivery and tissue engineering: One laboratory’s experience, Acc. Chem. Res., 33, 94, 10.1021/ar9800993 Lanza, 1997, Principles of Tissue Engineering, 405 Peppas, 1995, Recent advances on the use of biodegradable microparticles and nanoparticles in the controlled drug delivery, Int. J. Pharm., 116, 1, 10.1016/0378-5173(94)00324-X Zimmer, 1995, Microspheres and nanoparticles used in ocular drug delivery systems, Adv. Drug. Deliv. Rev., 16, 61, 10.1016/0169-409X(95)00017-2 Couvreur, 1986 Raney, 2000, Biomimetic transport, rational drug delivery, Biochem. Pharmacol., 59, 105, 10.1016/S0006-2952(99)00316-0 Uhrich, 1999, Polymeric systems for controlled drug release, Chem. Rev., 99, 3181, 10.1021/cr940351u Monfardini, 1998, Stabilization of substances in circulation, Bioconjug. Chem., 9, 418, 10.1021/bc970184f Torchilin, 1998, Polymer-coated long-circulating microparticulate pharmaceuticals, J. Microencapsul., 15, 1, 10.3109/02652049809006831 Wise, 1979, Lactide/glycolide acid polymers, 237 Jackanicz, 1973, Poly lactic acid as a biodegradable carrier for contraceptive steroids, Contraception, 8, 227, 10.1016/0010-7824(73)90033-4 Andersson, 1976, An injectable sustained release fertility control system, Contraception, 13, 375, 10.1016/S0010-7824(76)80047-9 Pitt, 1979, Sustained release drug delivery systems II: factors affecting release rate for poly(ϵ-caprolactone) and related biodegradable polyesters, J. Pharm. Sci., 68, 1534, 10.1002/jps.2600681219 Pitt, 1980, Biodegradable drug delivery systems based on aliphatic polyesters: application to contraceptives and narcotic antagonists, 19 Calvo, 1996, Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules and nanoemulsions as ocular drug carriers, J. Pharm. Sci., 85, 530, 10.1021/js950474+ Lescure, 1994, Preparation and characterization of novel poly(methylidene malonate 2.1.2.)-made nanoparticles, Pharm. Res., 9, 1270, 10.1023/A:1018986226557 Farrugia, 1999, Gelatin behavior in dilute aqueous solutions: Designing a nanoparticulate formulations, J. Pharm. Pharmacol., 51, 643, 10.1211/0022357991772925 Fernandez-Urrusuno, 1999, Enhancement of nasal absorption of insulin using chitosan nanopartilces, Pharm. Res., 16, 1576, 10.1023/A:1018908705446 Aynie, 1998, Alginate nanoparticles as a novel carrier for antisense oligonucleotide, 5 Vauthier, 1991, Methodology of ultradispersed polymer system, S.T.P. Pharm. Sci., 1, 109 Allemann, 1993, Drug-loaded nanoparticles-Preparation methods and drug targeting issues, Eur. J. Pharm., 39, 173 Couvreur, 1995, Controlled drug delivery with nanoparticles: Current possibilities and future trends, Eur. J. Pharm., 41, 2 Alonso, 1996, Nanoparticulate drug carrier technology, 203 Scholes, 1993, The preparation of sub-500 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery, J. Control. Rel., 25, 145, 10.1016/0168-3659(93)90103-C Zambaux, 1998, Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by double emulsion method, J. Control. Rel., 50, 31, 10.1016/S0168-3659(97)00106-5 Niwa, 1993, Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with d,l-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method and the drug release behavior, J. Control. Rel., 25, 89, 10.1016/0168-3659(93)90097-O Wehrle, 1995, The Influence of process parameters on the PLA nanoparticle size distribution evaluated by means of factorial design, J. Pharm. Biopharm., 41, 19 Murakami, 1996, Preparation of poly(d,l-lactide-co-glycolide) latex for surface modifying material by a double coacervation method, Proced. Intern. Symp. Control. Rel. Bioact. Mater., 23, 361 Birnbaum, 2000, Controlled release of β-estradiol from PLAGA microparticles: The effect of organic phase solvent on encapsulation and release, J. Control. Rel., 65, 375, 10.1016/S0168-3659(99)00219-9 Bodmeier, 1988, Solvent selection in the preparation of poly(d,l-lactide) microspheres prepared by the solvent evaporation method, Int. J. Pharm., 43, 179, 10.1016/0378-5173(88)90073-7 Arshaday, 1991, Preparation of porous and nonporous biodegradable polymeric hollow microspheres, J. Control. Rel., 17, 1 Allemann, 1992, Preparation of aqueous polymeric nanodispersions by a reversible salting-out process: influence of process parameters on particle size, Int. J. Pharm., 87, 247, 10.1016/0378-5173(92)90249-2 Allemann, 1993, Invitro extended-release properties of drug-loaded poly(d,l-lactic) acid nanoparticles produced by a salting-out procedure, Pharm. Res., 10, 1732, 10.1023/A:1018970030327 Leroux, 1995, New approach for the preparation of nanoparticles by an emulsification–diffusion method, Eur. J. Pharm. Biopharm., 41, 14 Quintanar, 1998, Influence of the stabilizer coating layer on the purification and freeze drying of poly (dl-lactic acid) nanoparticles prepared by emulsification-diffusion technique, J. Microencapsulation, 15, 107, 10.3109/02652049809006840 Tom, 1991, Particle formation with supercritical fluids — a review, J. Aerosol Sci., 22, 555, 10.1016/0021-8502(91)90013-8 Randolph, 1993, Sub-micron-sized biodegradable particles of poly(l-lactic acid) via the gas antisolvent spray precipitation process, Biotechnol. Prog., 9, 429, 10.1021/bp00022a010 L. Benedetti, A. Bertucco, M. Lora, P. Pallado, in: Atti del 3° Congresso I fluidi Supercriticai e le Loro Applicazioni, I. Kikic and P. Alessi (Eds.), Trieste, 1995, p. 221. Mishima, 2000, Microencapsulation of proteins by rapid expansion of supercritical solution with a nonsolvent, AIChE J., 46, 857, 10.1002/aic.690460418 Tom, 1991, Formation of bioerodiable polymeric microspheres and microparticles by rapid expansion of supercritical solution, Biotechnol. Prog., 7, 403, 10.1021/bp00011a004 Tom, 1994, Preparation of poly(l-lactic acid) and composite poly(l-lactic acid)-pyrene by rapid expansion of supercritical solution, J. Supercrit. Fluids, 7, 9, 10.1016/0896-8446(94)90003-5 Mawson, 1994, Formation of poly(1,1,2,2-tetrahydroperfluorodecyl acrylate) submicron fibers and particles from supercritical carbon dioxide solutions, Macromolecules, 28, 3182, 10.1021/ma00113a021 Pani, 1968, The degradation of n-butyl alpha-cyanoacrylate tissue adhesive, II, Surgery, 63, 481 Leonarda, 1970, Hemostatic application of alpha cyanoacrylates: bonding mechanism and physiological degradation of bonds, 185 Couvreur, 1978, Les perspectives d’utilisation des formes microdispersés comme vecteurs intracellulaires, Pharm. Acta Helv., 53, 341 Couvreur, 1979, Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphology and sorptive properties, J. Pharm. Pharmacol., 31, 331, 10.1111/j.2042-7158.1979.tb13510.x Behan, 1999, A study of the factors affecting the formation of poly(n-butylcyanoacrylate) nanoparticles, Proced. Intern. Symp. Control. Rel. Bioact. Mater., 26, 1134 Lherm, 1992, Alkylcynoacrylate drug carriers: II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length, Int. J. Pharm., 84, 13, 10.1016/0378-5173(92)90210-S De Keyser, 1989, Synthesis of 14C labeled acrylic derivatives: diethyl [3-14C] methylidenemalonate and isobutyl [3-14C] cyanoacrylate, J. Lable. Comp. Radiopharm., 27, 909, 10.1002/jlcr.2580270807 De Keyser, 1991, Poly(diethyl methylidenemalonate) nanoparticles as a potential drug carrier: preparation, distribution and elimination after intravenous and peroral administration to mice, J. Pharm. Sci., 80, 67, 10.1002/jps.2600800117 Mabela, 1993, Development of poly(dialkyl methylidenemalonate) nanoparticles as drug carriers, Int. J. Pharm., 92, 71, 10.1016/0378-5173(93)90265-H Breton, 1994, New poly(methylidene malonate 2.1.2) nanoparticles: Recent developments, Vol. 4, 161 Lescure, 1994, Preparation and charecterization of novel poly(methylidene malonoate 2.1.2.)-made nanoparticles, Pharm. Res., 11, 1270, 10.1023/A:1018986226557 Breton, 1998, Physico-chemical characterization, preparation and performance of poly(methylidene malonate 2.1.2) nanoparticles, Biomaterials, 19, 271, 10.1016/S0142-9612(97)00243-3 N. Bru-Magniez, X. Guillon, P. Breton, P. Couvreur, F. Lescure, C. Roques-Carmes, G. Riess, Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules, International Patent PCT WO 98/18455, 1998. N. Bru-Magniez, V. Larras, G. Riess, P. Breton, P. Couvreur, C. Roques-Carmes, Novel surfactant copolymers based on methylidene malonate, International Patent PCT WO 99/38898, 1999. Mitra, 1998, pH and thermoresponsive hydrogel nanoparticles, Proc. Intern. Symp. Control. Rel. Bioact. Mater., 25, 234 Mitra, 1998, Long circulating RES evading hydrophilic nanoparticles, Proc. Intern. Symp. Control. Rel. Bioact Mater., 25, 168 Gref, 1994, Biodegradable long circulating polymeric nanospheres, Science, 18, 1600, 10.1126/science.8128245 M. Amiji, K. Park, in: S.W. Shalaby, Y. Ikada, R. Langer, J. Williams, (Eds.), Polymers of Biological Significance, ACS Symp. Ser. 540, Washington, DC, 1994. Calvo, 1997, Novel hydrophilic chitosan and chitosan/polyethylene oxide nanoparticles as protein carriers, J. Appl. Polym. Sci., 63, 125, 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4 Calvo, 1997, Chitosan and chitosan/ethylene oxide–propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines, Pharm. Res., 14, 1431, 10.1023/A:1012128907225 Fernandez-urrusuno, 1999, Enhancement of nasal absorption of insulin using chitosan nanoparticles, Pharm. Res., 16, 1576, 10.1023/A:1018908705446 P. Calvo A.S. Boughaba, M. Appel, E. Fattal, M.J. Alonso, P. Couvreur, Oligonucleotide–chitosan nanoparticles as new gene therapy vector, Proc. 2nd World Meeting APGI/APV Paris, 1998, pp. 1111–1112. Mao, 1996, DNA–chitosan nanoparticles for the gene delivery, Proc. Intern. Symp. Control. Release. Bioact. Mater., 23, 401 Ray, 1999, Oral immunization with DNA–chitosan nanoparticles, Proc. Intern. Symp. Control. Release. Bioact. Mater., 26, 348 Truong-Le, 1997, Delivery of DNA vaccine using gelatin–DNA nanoparticles, Proc. Intern. Symp. Control. Rel. Bioact. Mater., 24, 39 Tian, 1999, Formulation and biological activity of antineoplastic proteoglycans derived from Mycobacterium vaccae in chitosan nanoparticles, J. Pharm. Pharmacol., 51, 151, 10.1211/0022357991772268 Tokumitsu, 1999, Chitosan–gadopenteic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: preparation by novel emulsion–droplet coalescence technique and characterization, Pharm. Res., 16, 1830, 10.1023/A:1018995124527 Vautheir, 1998, Pharmacokinetic and tissue disposition of oligonucleotide associated with alginate nanoparticles, Proc. Intern. Symp. Control. Rel. Bioact. Mater., 25, 228 Jung, 2000, Sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) facilitate the preparation of small negatively charged biodegradable nanospheres for protein delivery, J. Control. Rel., 67, 157, 10.1016/S0168-3659(00)00201-7 Breitenbach, 1999, Self-assembling colloidal carriers for protein delivery: nanoparticulate polymer protein conjugates with novel water soluble biodegradable comb polyesters, Proc. Intern. Symp. Control. Release. Bioact. Mater., 26, 159 Breitenbach, 1999, Oral and nasal administration of tetanus toxoid loaded nanoparticles consisting of novel charged biodegradable polyesters for mucosal vaccination, Proc. Intern. Symp. Control. Release. Bioact. Mater., 26, 348 Alenso, 1991, Approaches to improve the association of amikacin sulphate to poly(cyanoacrylate) nanoparticles, Int. J. Pharm., 68, 69, 10.1016/0378-5173(91)90128-B Ueda, 1998, Influence of the preparation methods on the drying release behavior of loperamide-loaded nanoparticles, J. Microencapsulation, 15, 361, 10.3109/02652049809006863 Couvreur, 1979, Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum, J. Pharm. Sci., 68, 1521, 10.1002/jps.2600681215 Radwan, 1995, In vitro evaluation of polyisobutylcyanoacrylate nanoparticles as a controlled drug carrier for theophylline, Drug Dev. Ind. Pharm., 21, 2371, 10.3109/03639049509070875 Egea, 1994, Entrapment of cisplatin into biodegradable polyalkylcyanoacrylate nanoparticles, Farmaco, 49, 211 Chukwu, 1999, Loading some psychopharmacologic agents onto poly(butyl-cyanoacrylate) nanoparticles-a means of targeting to the brain and improving therapeutic efficiency, Proced. Intern. Symp. Control. Rel. Bioact. Mater., 26, 1148 Vora, 1993, Investigation of the relative affinity of doxorubicin for neutral and negatively charged particulate carriers, Drug Dev. Ind. Pharm., 19, 759, 10.3109/03639049309062981 Martin, 1994, Study of the binding mechanisms of drugs onto polyalkylcyanoacrylate nanoparticles, J. Pharm. Belg., 49, 498 Benoit, 1994, Adsorption of beta-blocker onto polyisobutylcyanoacrylate nanoparticles measured by depletion and dielectric method, Pharm. Res., 11, 585, 10.1023/A:1018935103900 Yoo, 1999, Biodegradable nanoparticles containing doxorubicin–PLGA conjugate for sustained release, Pharm. Res., 16, 1114, 10.1023/A:1018908421434 Washington, 1990, Drug release from microdisperse systems. A critical review, Int. J. Pharm., 58, 1, 10.1016/0378-5173(90)90280-H Magenheim, 1991, Nanoparticle characterization: a comprehensive physicochemical approach, S.T.P. Pharm. Sci., 1, 221 El-Samaligly, 1986, Polyalkylcyanoacrylate nanocapsules, J. Pharm. Pharmacol., 38, 216, 10.1111/j.2042-7158.1986.tb04547.x LeRay, 1994, End-chain radiolabeling and in vitro stability studies of radiolabeled poly(hydroxy) nanoparticles, J. Pharm. Sci., 83, 845, 10.1002/jps.2600830618 Fresta, 1995, Pefloxacin mesilate- and ofloxacin-loaded polyethylcyanoacrylate nanoparticles; characterization of the colloidal drug carrier formulation, J. Pharm. Sci., 84, 895, 10.1002/jps.2600840721 Cavallaro, 1994, Entrapment of β-lactams antibiotics in polyethylcyanoacrylate nanoparticles: studies on the possible in vivo application of this colloidal delivery system, Int. J. Pharm., 111, 31, 10.1016/0378-5173(94)90399-9 Leavy, 1990, Drug release from submicron O/W emulsion: A new in vitro kinetic evaluation model, Int. J. Pharm., 66, 29, 10.1016/0378-5173(90)90381-D Jalil, 1990, Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties, J. Microencapsul., 7, 297, 10.3109/02652049009021842 Magenheim, 1993, A new in vitro technique for the evaluation of drug release profiles from colloidal carriers-ultrafiltration technique at low pressure, Int. J. Pharm., 94, 115, 10.1016/0378-5173(93)90015-8 Rodrigues Jr, 1995, Premaquine-loaded poly(lactide) nanoparticles: physicochemical study and acute tolerance in mice, Int. J. Pharm., 126, 253, 10.1016/0378-5173(95)04135-4 Polakovic, 1999, Lidocaine loaded biodegradable nanospheres. II. modeling of drug release, J. Control. Rel., 60, 169, 10.1016/S0168-3659(99)00012-7 Lu, 1999, A method of the preparation of polymeric nanocapsules without stabilizer, J. Control. Rel., 61, 107, 10.1016/S0168-3659(99)00112-1 Muller, 1993, Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908, Int. J. Pharm., 89, 25, 10.1016/0378-5173(93)90304-X Van Oss, 1978, Phagocytosis as a surface phenomenon, Annu. Rev. Microbiol., 32, 19, 10.1146/annurev.mi.32.100178.000315 Allemann, 1997, Kinetics of blood component-adsorption on poly(d,l-lactide) nanoparticles: Evidence of compliment C3 component involvement, J. Biomed. Mater. Res., 37, 229, 10.1002/(SICI)1097-4636(199711)37:2<229::AID-JBM12>3.0.CO;2-9 Blunk, 1996, Kinetics of plasma protein adsorption on model particles for controlled drug delivery and drug targeting, Eur. J. Pharm. Biopharm., 42, 262 Thode, 1997, Determination of plasma protein adsorption on magnetic iron oxide: sample preparation, Pharm. Res., 14, 905, 10.1023/A:1012104017761 Thode, 1997, Influence of sample preparation on plasma protein adsorption patterns on polysaccharide-stabilized iron oxide particles and end-terminal microsequencing of unknown proteins, J. Drug Target., 5, 35, 10.3109/10611869708995856 Lück, 1998, Plasma protein adsorption on biodegradable microspheres consisting of poly(d,l-lactide-co-glycolide), poly(l-lactide) or ABA triblock copolymers containing poly(oxyethylene), J. Control. Rel., 55, 107, 10.1016/S0168-3659(98)00030-3 Gref, 1995, The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres, Adv. Drug Deliv. Rev., 16, 215, 10.1016/0169-409X(95)00026-4 Peracchia, 1999, Visualization of in vitro protein-rejecting properties of PEGylated stealth® polycyanoacrylate nanoparticles, Biomaterials, 20, 1269, 10.1016/S0142-9612(99)00021-6 Ratner, 1987, Biomaterial surface, J. Biomed. Mat. Res. Appl. Biomat., 21, 59 Carstensen, 1991, Adsorption of ethoxylated surfactants on nanoparticles. I. Characterization by hydrophilic interaction chromatography, Int. J. Pharm., 67, 29, 10.1016/0378-5173(91)90262-M Gref, 1994, Biodegradable long-circulating polymeric nanoparticles, Science, 263, 1600, 10.1126/science.8128245 Joen, 1991, Protein-surface interactions in the presence of polyethylene oxide. I. Simplified theory, J. Colloid. Interf. Sci., 142, 149, 10.1016/0021-9797(91)90043-8 Bazile, 1995, Stealth Me-PEG–PLA nanoparticles avoid uptake by the mononuclear phagocyte system, J. Pharm. Sci., 84, 493, 10.1002/jps.2600840420 Tobio, 1998, Stealth PLA–PEG nanoparticles as protein carriers for nasal administration, Pharm. Res., 15, 270, 10.1023/A:1011922819926 Gref, 1999, Polyoxyethylene-coated nanospheres: effect of coating on zeta potential and phagocytosis, Polymer Int., 48, 251, 10.1002/(SICI)1097-0126(199904)48:4<251::AID-PI104>3.0.CO;2-4 Govender, 2000, PLA–PEG nanoparticles for site specific delivery: drug incorporation studies, J. Control. Rel., 64, 269 Kim, 1998, Preparation and characterization of biodegradable nanospheres composed of methoxy poly(ethylene glycol) and dl-lactide block copolymer as novel drug carriers, J. Control. Rel., 56, 197, 10.1016/S0168-3659(98)00083-2 Peracchia, 1999, Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and spleenic targeting, J. Control. Rel., 60, 121, 10.1016/S0168-3659(99)00063-2 Gessnerl, 1999, Plasma protein adsorption on poly(ethylene-glycol) (PEG) modified polystyrene nanoparticles: influence of PEG surface density, Proc. Intern. Symp. Control. Rel. Bioact. Mater., 26, 597 Peracchia, 1997, PEG-coated injectable nanospheres prepared from amphiphilic diblock and multiblock copolymers: investigation of drug encapsulation and release characteristics, J. Control. Rel., 46, 223, 10.1016/S0168-3659(96)01597-0 Peracchia, 1996, PEG–PIBCA nanoparticles with different PEG-coating configurations formed by chemical coupling of PEG, Proced. Intern. Symp. Control. Rel. Bioact. Mater., 23, 395 Peracchia, 1997, Development of sterically stabilized poly(isobutyl-2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol), J. Biomed. Mater. Res., 34, 317, 10.1002/(SICI)1097-4636(19970305)34:3<317::AID-JBM6>3.0.CO;2-N Peracchia, 1998, PEGylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate–hexadecyl cyanoacrylate amphiphilic copolymer, Pharm. Res., 15, 550, 10.1023/A:1011973625803 Peracchia, 1997, Compliment consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl-2-cyanoacrylate) nanoparticles, Life Sci., 61, 741, 10.1016/S0024-3205(97)00539-0 Jaeghere, 1999, Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles: Influence on the physical stability and in vitro cell uptake, Pharm. Res., 16, 859, 10.1023/A:1018826103261 Vittaz, 1996, Effect of PEO surface density on long-circulating PLA–PEO nanoparticles which are very low complement activators, Biomaterials, 17, 1575, 10.1016/0142-9612(95)00322-3 Ha, 1999, Poly(ethylene oxide)–poly(propylene oxide)–poly(ethylene oxide) (Plunoric)/poly(ϵ-caprolactone) (PCL) amphiphilic block copolymeric nanospheres I. Preparation and characterization, J. Control. Rel., 62, 381, 10.1016/S0168-3659(99)00167-4 Storm, 1995, Surface modification of nanoparticles to oppose uptake by the mononuclear system, Adv. Drug Deliv. Rev., 17, 31, 10.1016/0169-409X(95)00039-A Illum, 1983, Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration, J. Pharm. Sci., 72, 1086, 10.1002/jps.2600720933 Illum, 1984, The organ uptake of intravenously administered colloidal particles can be altered using a non-ionic surfactant (poloxamer 338), FEBS Letts., 167, 79, 10.1016/0014-5793(84)80836-4 Rudt, 1993, In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. III. Uptake of differently sized surface-modified particles, and its correlation to particle properties and in vivo distribution, Eur. J. Pharm. Sci., 1, 31, 10.1016/0928-0987(93)90015-3 Illum, 1993, The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer poloxamine 908, Int. J. Pharm., 89, 25 Moghimi, 1997, Single dose of iv injected poloxamine coated long-circulating particle triggers macrophage clearance of subsequent doses in rats, Clin. Sci., 93, 371, 10.1042/cs0930371 Demoy, 1999, Spleen capture of nanoparticles: Influence of animal species and surface characteristics, Pharm. Res., 16, 37, 10.1023/A:1018858409737 Shinoda, 1999, Nanosphere coated with lactosyl-polystyrene polymer as a targeting carrier to hepatocytes, Drug Deliv., 6, 147, 10.1080/107175499266896 Cho, 1997, Simple preparation of nanoparticles coated with carbohydrate-carrying polymers, Biomaterials, 18, 323, 10.1016/S0142-9612(96)00138-X Maruyama, 1997, Nanoparticle DNA carrier with poly(l-lysine) grafted polysaccharide copolymer and poly(d,l-lactic acid), Bioconjug. Chem., 8, 735, 10.1021/bc9701048 Duchene, 1999, Cyclodextrins and carrier systems, J. Control. Rel., 62, 263, 10.1016/S0168-3659(99)00046-2 Raeissi, 1989, In vitro characterization of blood–brain barrier permeability to delta sleep-inducing peptide, J. Pharm. Pharmacol., 41, 848, 10.1111/j.2042-7158.1989.tb06385.x Zlokovich, 1989, The in vivo approaches for studying peptide interaction at the blood–brain barrier, Peptides, 10, 249 Schroeder, 1996, Nanoparticles, a drug carrier system to pass the blood–brain barrier, permit central analgesic effects of i.v. dalargin injections, Brain Res., 710, 121, 10.1016/0006-8993(95)01375-X Schroeder, 1998, A efficacy of oral dalargin-loaded nanoparticle delivery across the blood–brain barrier, Peptide, 19, 777, 10.1016/S0196-9781(97)00474-9 Alyautdin, 1995, Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles, Eur. J. Pharm. Biopharm., 41, 44 Borchardt, 1994, Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers, Int. J. Pharmacol., 110, 29, 10.1016/0378-5173(94)90372-7 Troster, 1990, Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants, Int. J. Pharm., 61, 85, 10.1016/0378-5173(90)90047-8 Steiniger, 1999, The influence of polysorbate 80-coated nanoparticles on bovine brain capillary endothelial cells in vitro, Proced. Intern. Symp. Control. Rel. Bioact. Mater., 26, 790 Olivier, 1999, Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity, Pharm. Res., 16, 1836, 10.1023/A:1018947208597 Gulyaev, 1999, Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles, Pharm. Res., 16, 1564, 10.1023/A:1018983904537 Alyautdin, 1997, Delivery of lopermide across the blood–brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles, Pharm. Res., 14, 25, 10.1023/A:1012098005098 Alyautdin, 1998, Significant entry of tubocurarin into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: in situ brain perfusion study, J. Microencapsulation, 15, 67, 10.3109/02652049809006836 Schroeder, 1998, Nanoparticle technology for delivery of drugs across the blood–brain-barrier, J. Pharm. Sci., 87, 1305, 10.1021/js980084y Couvreur, 1993, Nano- and microparticles for the delivery of peptides and proteins, Adv. Drug Deliv. Rev., 5, 141, 10.1016/0169-409X(93)90046-7 Uchida, 1996, Instability of bovine insulin in poly(lactide-co-glycolide) (PLGA) microspheres, Chem. Pharm. Bull., 44, 235, 10.1248/cpb.44.235 Lin, 1997, A novel biodegradable system based on gelatin NPs and poly(lactic-co-glycolic acid) microspheres for protein and peptide drug delivery, J. Pharm. Sci., 86, 891, 10.1021/js970084i Wang, 1999, A heterogeneously structured composite based on poly(lactic-co-glycolic acid) microspheres and poly(vinyl alcohol) hydrogel nanoparticles for long-term protein drug delivery, Pharm. Res., 16, 1430, 10.1023/A:1018911411381 Gasper, 1998, Formulation of l-aspargainase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release, J. Control. Rel., 52, 53, 10.1016/S0168-3659(97)00196-X Fishbein, 2000, Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis, J. Control. Rel., 65, 221, 10.1016/S0168-3659(99)00244-8 Kawashima, 1999, Pulmonary delivery of insulin with nebulized dl-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect, J. Control. Rel., 62, 279, 10.1016/S0168-3659(99)00048-6 Carino, 2000, Nanosphere based oral insulin delivery, J. Control. Rel., 65, 261, 10.1016/S0168-3659(99)00247-3